Advertisement

Topics

Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis

2016-07-05 22:34:30 | BioPortfolio

Published on BioPortfolio: 2016-07-05T22:34:30-0400

Clinical Trials [40 Associated Clinical Trials listed on BioPortfolio]

A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination

The primary objective of this study is to investigate the effect of steady state pirfenidone on the pharmacokinetics of nintedanib and its metabolites following oral administration of 2403...

Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

This is a phase IV, twelve week, open label, randomized, parallel group study to assess safety and tolerability of combined treatment with nintedanib and pirfenidone. A secondary objectiv...

The Safety and Tolerability of Pirfenidone for BOS After HCT

This is a phase 2, open label, single center randomized clinical trial to determine the tolerability and safety of pirfenidone in patients with BOS associated with lung GVHD after hematopo...

Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer

RATIONALE: Pirfenidone may prevent or lessen fibrosis caused by radiation therapy. PURPOSE: Pilot trial to study the effectiveness of pirfenidone in preventing or lessening fibrosis in pa...

Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 mg/d compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to as...

PubMed Articles [25 Associated PubMed Articles listed on BioPortfolio]

Effect of pirfenidone on gastric emptying in a rat model.

Gastrointestinal (GI) adverse events (AEs) are commonly reported in patients with idiopathic pulmonary fibrosis who are treated with pirfenidone. Taking pirfenidone with a substantial amount of food o...

Pirfenidone Inhibits Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway.

BACKGROUND Hepatocellular carcinoma (HCC) is the most important cause of cancer-related deaths worldwide. Pirfenidone is an orally available small molecule with therapeutic potential for fibrotic dise...

Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report.

Pirfenidone was approved in 2014 for the treatment of idiopathic pulmonary fibrosis. Pirfenidone inhibits several factors such as tissue growth factor-β and platelet-derived growth factor, leading to...

Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model.

Radiation-induced complications of the respiratory system are a common side effect of thoracic radiotherapy with no viable treatment option. Here, we investigated the potential therapeutic effect of t...

Pirfenidone prevents radiation-induced intestinal fibrosis in rats by inhibiting fibroblast proliferation and differentiation and suppressing the TGF-β1/Smad/CTGF signaling pathway.

Radiation-induced intestinal fibrosis (RIF) is a chronic toxicity following radiation, and can be very difficult to treat. Pirfenidone is a promising anti-fibrotic agent that inhibits fibrosis progres...

Medical and Biotech [MESH] Definitions

None available.

More From BioPortfolio on "Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial